• Clinical Trials - Non-Hodgkin's Lymphoma

    Study Objective Contact
    CALGB 50102: S0016: A Phase III Trial Of CHOP + Rituximab VS. CHOP + Iodine131-Labeled Monoclonal Anti-B1 Antibody (TOSITUMOMAB) For Treatment Of Newly Diagnosed Follicular Non-Hodgkins's Lymphomas [LCID Study Number: 2004-052] The purpose of this study is to find out if a combination of drugs (called CHOP) followed by an antibody (rituximab) or a radioactive antibody (Iodine-131 anti-B1 antibody - also called tositumomab), is able to stop the growth of cancer and to see if this treatment is tolerable. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Arthur P. Rabinowitz, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar.